Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.63 |
| ▸ | AR | P10275 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15314493 | 1.00 | HRH3 (1.00) | HRH3SIGMAR1ARMEN1ALDH1A1 | |
| SCHEMBL437365 | 1.00 | HRH3 (1.00) | HRH3SIGMAR1ARMEN1ALDH1A1 | |
| SCHEMBL450394 | 1.00 | HRH3 (1.00) | HRH3SIGMAR1ARMEN1ALDH1A1 | |
| SCHEMBL24580904 | 0.86 | HRH3 (0.75) | HRH3SIGMAR1AREPHX2 | |
| SCHEMBL12883193 | 0.84 | HRH3 (0.72) | HRH3SIGMAR1ARMEN1ALDH1A1 | |
| SCHEMBL12836573 | 0.84 | HRH3 (0.72) | HRH3SIGMAR1ARMEN1ALDH1A1 | |
| SCHEMBL24581185 | 0.83 | HRH3 (0.71) | HRH3SIGMAR1ALDH1A1 | |
| SCHEMBL24581220 | 0.83 | HRH3 (0.70) | HRH3SIGMAR1ARMEN1ALDH1A1 | |
| SCHEMBL24581225 | 0.82 | HRH3 (0.70) | HRH3SIGMAR1AR | |
| SCHEMBL24581211 | 0.81 | HRH3 (0.67) | HRH3SIGMAR1ARMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150216861-A1 | CYCLOPROPYL AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-08-06 | — | — | US | claimed |
| US-9029381-B2 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2015-05-12 | — | — | US | claimed |
| EP-2805937-A1 | Cyclopropyl amide derivatives | AstraZeneca AB (SE) | 2014-11-26 | — | — | EP | claimed |
| EP-2195293-B1 | CYCLOPTOPYL AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-10-16 | — | — | EP | claimed |
| US-20120065193-A1 | Cyclopropyl Amide Derivatives '978 | ASTRAZENECA AB (SE) | 2012-03-15 | — | — | US | claimed |
| EP-2195293-A2 | CYCLOPTOPYL AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2010-06-16 | — | — | EP | claimed |
| US-20090076020-A1 | Cyclopropyl Amide Derivatives 978 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | claimed |
| WO-2009024823-A2 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | claimed |
| US-20150216861-A1 | CYCLOPROPYL AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-08-06 | — | — | US | disclosed |
| US-9029381-B2 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2015-05-12 | — | — | US | disclosed |
| EP-2805937-A1 | Cyclopropyl amide derivatives | AstraZeneca AB (SE) | 2014-11-26 | — | — | EP | disclosed |
| EP-2253615-B1 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2014-07-09 | — | — | EP | disclosed |
| EP-2195293-B1 | CYCLOPTOPYL AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-10-16 | — | — | EP | disclosed |
| US-20120065193-A1 | Cyclopropyl Amide Derivatives '978 | ASTRAZENECA AB (SE) | 2012-03-15 | — | — | US | disclosed |
| EP-2253615-A1 | Cyclopropyl amide derivatives | AstraZeneca AB (SE) | 2010-11-24 | — | — | EP | disclosed |
| EP-2195293-A2 | CYCLOPTOPYL AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2010-06-16 | — | — | EP | disclosed |
| US-20090076020-A1 | Cyclopropyl Amide Derivatives 978 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076020-A1 | Cyclopropyl Amide Derivatives 978 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| WO-2009024823-A2 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009024823-A2 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216861-A1 | CYCLOPROPYL AMIDE DERIVATIVES | HRH4, HRH2, HRH3 | HRH3 3/4885SIGMAR1 82/4885AR 1269/4885 |
| US-20090076020-A1 | Cyclopropyl Amide Derivatives 978 | HRH4, HRH2, HRH3 | HRH3 3/4885SIGMAR1 122/4885AR 1106/4885 |
| US-20120065193-A1 | Cyclopropyl Amide Derivatives '978 | HRH2, HRH4, HRH3 | HRH3 3/4885SIGMAR1 155/4885AR 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.